Investigation to Understand and Optimize Psilocybin

ConditionDepression
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorCharles Raison

About this trial

This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be associated with long-term treatment outcomes.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Psilocybin
  • Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
  • Sham taVNS

Treatment groups

141 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Charles Raison

Lead sponsor

Vail Health Behavioral Health

Sponsor institution

Usona Institute

Collaborator

Tiny Blue Dot Foundation

Collaborator

Steadman Philippon Research Institute

Collaborator

Emory University

Collaborator